Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 4,767 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 4,767 shares of Stoke Therapeutics stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $152,687.01. Following the completion of the transaction, the insider directly owned 25,655 shares in the company, valued at $821,729.65. The trade was a 15.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Barry Ticho also recently made the following trade(s):

• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04.
• On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock opened at $32.14 on Wednesday. The company has a market capitalization of $2.07 billion, a P/E ratio of -9.62 and a beta of 1.20. Stoke Therapeutics, Inc. has a 1 year low of $18.00 and a 1 year high of $40.22. The company’s fifty day moving average is $30.81 and its two-hundred day moving average is $32.21.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The business had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. As a group, equities analysts expect that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on STOK shares. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Guggenheim reissued a “buy” rating and issued a $60.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Canaccord Genuity Group cut their price target on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. Finally, The Goldman Sachs Group initiated coverage on shares of Stoke Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $43.00.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in STOK. BlackRock Inc. purchased a new position in shares of Stoke Therapeutics during the 2nd quarter worth approximately $192,307,000. RTW Investments LP boosted its stake in shares of Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock valued at $176,057,000 after buying an additional 423,331 shares in the last quarter. Redmile Group LLC boosted its stake in shares of Stoke Therapeutics by 3.2% in the first quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock valued at $135,584,000 after buying an additional 130,050 shares in the last quarter. Morgan Stanley grew its holdings in Stoke Therapeutics by 0.3% during the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after acquiring an additional 9,108 shares during the period. Finally, State Street Corp grew its holdings in Stoke Therapeutics by 75.2% during the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after acquiring an additional 1,072,176 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.